ASCO GU 2018: Preliminary results from patients with urothelial carcinoma in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody
San Francisco, CA (UroToday.com) Immune checkpoint inhibitors (ICI) continue to be tested in all different cancers in all different stages. In general, when success is identified, objective response rates seem to be about 15-20% of the population, but many of these patients have a durable response. Bladder cancer has been no exception, and there has been a great deal of success in the metastatic bladder cancer space.
ASCO GU 2018: Results of Phase I Plus Expansion Cohorts of Cabozantinib Plus Nivolumab and Cabozantinib/nivolumab Plus Ipilimumab In Patients With Metastatic Urothelial Carcinoma And Other Genitourinary Malignancies
San Francisco, CA (UroToday.com) Dr. Nadal and colleagues presented results of their phase I trial assessing combinations of cabozantinib, nivolumab and ipilimumab in patients with metastatic genitourinary malignancies. Tolerability and efficacy of cabozantinib + nivolumab and cabozantinib + nivolumab + ipilimumab was demonstrated in an initial phase I cohort , prompting longer follow-up and the addition of expansion cohorts. The objective of this study is to further evaluate both combinations among patients with metastatic urothelial carcinoma and other genitourinary malignancies.
ASCO GU 2018: Lessons Learned From New Guidelines and How They Have Changed Management of Muscle-Invasive Bladder Cancer
San Francisco, CA (UroToday.com) Dr. Holzbeierlein began his discussion on the new muscle-invasive bladder cancer (MIBC) guidelines,1 a collaborative multi-disciplinary effort led by Dr. Sam Chang that involved input from all the major organizations, including AUA, ASCO, ASTRO, and patient advocates. The final analysis was built on prior work by Dr. Chou’s AHRQ systematic reviews (through 2015).
ASCO GU 2018: Between-surgeon variation in surgical quality performance as an indicator of outcomes in radical cystectomy for bladder cancer
San Francisco, CA (UroToday.com) Dr. Rudzinski and colleagues presented their findings of between surgeon variation in surgical quality performance after radical cystectomy. Indeed, radical cystectomy for bladder cancer is a complex surgical oncology procedure and given the degree of skill required to perform the procedure, it is plausible that outcomes may vary among surgeons.
ASCO GU 2018: Differences in survival among non-urothelial bladder cancers: Analyses of SEER 1988-2008
San Francisco, CA (UroToday.com) Urothelial carcinoma of the bladder represents the vast majority of bladder cancers diagnosed in the United States. Variant histologies of urothelial cancer as well as non-urothelial bladder cancer represent a unique subset of patients. Non-urothelial bladder cancers encompass only a very small proportion of all diagnosed bladder cancers, but are generally thought to be more aggressive than urothelial bladder cancer; management guidelines are limited due to the relative rarity of these conditions.
ASCO GU 2018: Update on The Cancer Genome Atlas
San Francisco, CA (UroToday.com) Dr. Lerner provided the second Urothelial Carcinoma Keynote Lecture and provided an update on the current status of translational observations from mutational profiling of muscle invasive bladder cancer (MIBC). There has been significant much-publicized work in this field, and it hoping will lead to prime-time decision-making tools in the near future. Specifically he focused on the updates to TCGA data.
ASCO GU 2018: Use of Molecular Markers in Bladder Preservation Therapy
San Francisco, CA (UroToday.com) As part of the Current and Future Directions of Muscle-Invasive Bladder Cancer (MIBC) session at GU ASCO, Dr. Peter Hoskin from the UK provided an update regarding the use of molecular markers in bladder preservation therapy. Dr. Hoskin started by noting that based on a propensity score analysis of highly selected patients with MIBC from the Princess Margaret Cancer Centre, there was no difference in survival between patients undergoing radical cystectomy or bladder-sparing trimodal therapy over a median follow-up of > 4 years .